Larimar Therapeutics Files 8-K
Ticker: LRMR · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1374690
| Field | Detail |
|---|---|
| Company | Larimar Therapeutics, Inc. (LRMR) |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-update, financials
Related Tickers: LRMR
TL;DR
Larimar (LRMR) filed an 8-K on 9/29/25, mostly standard updates.
AI Summary
On September 29, 2025, Larimar Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits. Larimar Therapeutics, Inc. was formerly known as Zafgen, Inc. and is incorporated in Delaware.
Why It Matters
This 8-K filing provides an update on Larimar Therapeutics' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report and does not appear to contain any material non-public information that would immediately impact the company's risk profile.
Key Players & Entities
- Larimar Therapeutics, Inc. (company) — Registrant
- Zafgen, Inc. (company) — Former company name
- September 29, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing for Larimar Therapeutics, Inc.?
The filing indicates that it concerns 'Other Events' and 'Financial Statements and Exhibits', suggesting it's for routine corporate updates and financial reporting.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on September 29, 2025.
What was Larimar Therapeutics, Inc. formerly known as?
Larimar Therapeutics, Inc. was formerly known as Zafgen, Inc.
In which state is Larimar Therapeutics, Inc. incorporated?
Larimar Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Larimar Therapeutics, Inc.?
The business address is Three Bala Plaza East, Suite 506, Bala Cynwyd, Pennsylvania, 19004.
Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-09-29 07:00:16
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market
Filing Documents
- d24800d8k.htm (8-K) — 26KB
- d24800dex991.htm (EX-99.1) — 58KB
- d24800dex992.htm (EX-99.2) — 26KB
- g24800ex99_2s10g1.jpg (GRAPHIC) — 92KB
- g24800ex99_2s11g1.jpg (GRAPHIC) — 67KB
- g24800ex99_2s12g1.jpg (GRAPHIC) — 107KB
- g24800ex99_2s13g1.jpg (GRAPHIC) — 101KB
- g24800ex99_2s14g1.jpg (GRAPHIC) — 118KB
- g24800ex99_2s15g1.jpg (GRAPHIC) — 77KB
- g24800ex99_2s16g1.jpg (GRAPHIC) — 69KB
- g24800ex99_2s17g1.jpg (GRAPHIC) — 99KB
- g24800ex99_2s18g1.jpg (GRAPHIC) — 68KB
- g24800ex99_2s1g1.jpg (GRAPHIC) — 46KB
- g24800ex99_2s2g1.jpg (GRAPHIC) — 186KB
- g24800ex99_2s3g1.jpg (GRAPHIC) — 163KB
- g24800ex99_2s4g1.jpg (GRAPHIC) — 108KB
- g24800ex99_2s5g1.jpg (GRAPHIC) — 90KB
- g24800ex99_2s6g1.jpg (GRAPHIC) — 90KB
- g24800ex99_2s7g1.jpg (GRAPHIC) — 119KB
- g24800ex99_2s8g1.jpg (GRAPHIC) — 76KB
- g24800ex99_2s9g1.jpg (GRAPHIC) — 72KB
- g24800larimar.jpg (GRAPHIC) — 4KB
- 0001193125-25-221538.txt ( ) — 2659KB
- lrmr-20250929.xsd (EX-101.SCH) — 3KB
- lrmr-20250929_lab.xml (EX-101.LAB) — 18KB
- lrmr-20250929_pre.xml (EX-101.PRE) — 11KB
- d24800d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 99.1 Press Release issued by Larimar Therapeutics, Inc. on September 29, 2025* 99.2 Larimar Therapeutics, Inc. Conference Call Presentation, dated September 29, 2025* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer Date: September 29, 2025